is retatrutide fda approved october 2025 Side Effects Guide: 21 Proven Remedies That Work TRIUMPH-4: Retatrutide Beat Every Prediction

Alcohol use and poor sleep quality: A longitudinal twin study across 36 years

Key Takeaways Retatrutide targets three hormones (GLP-1, GIP, glucagon), tirzepatide targets two (GLP-1, GIP), and semaglutide targets one (GLP-1) At 68 weeks, retatrutide achieved 28.7% average weight loss, tirzepatide approximately 22%, and semaglutide around 17% on the highest doses Side effects are similar across all three medications, mainly digestive issues like nausea and diarrhoea Retatrutide is not yet approved and won't be available until mid-2026 at the earliest Retatrutide is not yet approved and is not currently available in the UK Tirzepatide (Mounjaro) and semaglutide (Wegovy) are both available now in the UK through NHS or private providers By entering I agree to the Terms and Conditions

Cost: 20-30% of weight lost comes from muscle

Are GLP-1s Performance-Enhancing Drugs